- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
COVID-19 Treatment: Glenmark gets DCGI nod to launch oral antiviral drug favipiravir
![COVID-19 Treatment: Glenmark gets DCGI nod to launch oral antiviral drug favipiravir COVID-19 Treatment: Glenmark gets DCGI nod to launch oral antiviral drug favipiravir](https://medicaldialogues.in/h-upload/2020/06/10/750x450_130115-126016-white-medicines.webp)
New Delhi: Drug firm Glenmark Pharmaceuticals on Friday said it has received approval from the Indian drug regulator to launch oral antiviral drug favipiravir for treatment of mild to moderate COVID-19 patients in the country.
It is for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation, Glenmark Pharmaceuticals said in a statement.
The company has received the manufacturing and marketing approval from Drugs Controller General of India (DCGI) to launch favipiravir for the treatment of mild to moderate COVID-19 patients, it said.
"This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of the accelerated approval process, considering the emergency situation and unmet medical need of the COVID-19 outbreak," Glenmark said.
Shares of Glenmark Pharmaceuticals closed at Rs 409.10 per scrip on the BSE, up 0.93 per cent from its previous close.
Read also: Glenmark Pharmaceuticals gets USFDA nod for Fingolimod Capsules
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751